Decoding the selectivity of eIF2α holophosphatases and PPP1R15A inhibitors
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The reversible phosphorylation of proteins controls most cellular functions. Protein kinases have been popular drug targets, unlike phosphatases, which remain a drug discovery challenge. Guanabenz and Sephin1 are selective inhibitors of the phosphatase regulatory subunit PPP1R15A (R15A) that prolong the benefit of eIF2α phosphorylation, thereby protecting cells from proteostatic defects. In mice, Sephin1 prevents two neurodegenerative diseases, Charcot–Marie–Tooth 1B (CMT-1B) and SOD1-mediated amyotrophic lateral sclerosis (ALS). However, the molecular basis for R15A inhibition is unknown. Here we reconstituted human recombinant eIF2α holophosphatases, R15A–PP1 and R15B–PP1, whose activity depends on both the catalytic subunit PP1 (protein phosphatase 1) and either R15A or R15B. This system enabled the functional characterization of these holophosphatases and revealed that Guanabenz and Sephin1 induced a selective conformational change in R15A, detected by resistance to limited proteolysis. This altered the recruitment of eIF2α, preventing its dephosphorylation. This work demonstrates that regulatory subunits of phosphatases are valid drug targets and provides the molecular rationale to expand this concept to other phosphatases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
Harding, H. P., Zhang, Y., Scheuner, D., Chen, J.-J., Kaufman, R. J., & Ron, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809632106 · Cited by 267
Cited by
Pharmacological targeting of endoplasmic reticulum stress in disease
Marciniak, S. J., Chambers, J. E., & Ron, D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00320-3 · Cited by 520
Pharmacological targeting of the unfolded protein response for disease intervention
Hetz, C., Axten, J. M., & Patterson, J. B. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0326-2 · Cited by 255
Young, L. C., Hartig, N., Boned del Río, I., Sari, S., Ringham-Terry, B., Wainwright, J. R., Jones, G. G., McCormick, F., & Rodriguez-Viciana, P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720352115 · Cited by 98
“Allosteric inhibition is an emerging theme in phosphatases (51–54), and there is now proof of concept of specific inhibition of a PP1 holophosphatase by small molecules binding to its regulatory subunit (55).”
BackgroundThe unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial
Dalla Bella, E., Bersano, E., Antonini, G., Borghero, G., Capasso, M., Caponnetto, C., Chiò, A., Corbo, M., Filosto, M., Giannini, F., et al. (2021) · Brain · doi:10.1093/brain/awab167 · Cited by 59
Yan, Y., Shetty, M., Harding, H. P., George, G., Zyryanova, A., Labbé, K., Mafi, A., Hao, Q., Sidrauski, C., & Ron, D. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320013121 · Cited by 7
Metadata
- Authors
- Carrara, M., Sigurdardottir, A., & Bertolotti, A.
- Venue
- Nature Structural & Molecular Biology
- Published
- 2017-07-31
- Volume
- 24
- Issue
- 9
- Pages
- 708-716
- ISSN
- 1545-9985 (ISSN-L)
- 1545-9993
- OpenAlex
- W2741040341
- Cited by
- 88
- References
- 3
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.